VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 15, 2015) - M Pharmaceutical Inc. (CSE:MQ)(OTCQB:MPHMF) (the "Company"), a Canadian company committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes, announced today that it received approval to begin trading on the OTCQB marketplace. Companies trading on the OTCQB may be bought or sold in a manner almost identical to those trading on the NYSE or NASDAQ, via either institutional, online or retail brokers.
"This milestone opens the doors to institutional investors and market makers who were not previously able to buy and sell shares of our Company. Now they may execute on unsolicited orders and also make recommendations to clients as they so choose. It also now gives individual investors in the United States the ability to trade shares of our Company," said George Tsafalas, Director at M Pharmaceutical Inc.
"The high standard for compliance and related information requirements of OTCQB approval provides our investors greater confidence and matches our commitment to accountability and transparency," said Dr. Martin Mintchev, new President & Chief Executive Officer of the Company.
The Company also announced that it has issued a total of 1,325,000 options to directors and consultants of the Company, including those sitting on its advisory board. These options are exercisable at $0.17 for a period of 5 years, and vest over in equal portions over the next 3 years.
About M Pharmaceutical Inc.
M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes. The Company currently has or has agreed to acquire the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. Commercial development of eMosquito, Trimeo and Trimtec biomedical technologies will require successful coordination and execution of a wide variety of technology disciplines.